• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Clinical trial underway for feline herpesvirus treatment in shelter cats

June 15, 2020

Shelter cats with FHV-1 are more likely to be euthanized than adopted. The ultimate goal of this new study is to give shelter cats a better chance at a full and healthy life.

Experts believe upwards of 95% of cats worldwide have been exposed to feline herpesvirus type 1 (FHV-1), and shelter cats are no exception. In fact, shelter cats are one of the most at-risk groups for FHV-1 infection due to the close living quarters and high population density at these facilities.

To save shelter cats’ eyes and lives, Morris Animal Foundation–funded researchers at Louisiana State University School of Veterinary Medicine (LSU SVM) are conducting a clinical trial of three common antiviral drugs to determine which is best suited to treat this highly contagious disease in animal shelters.

Advertisement

“FHV-1 is a huge welfare issue for shelter cats and it is important that we find a viable method to address it,” Morris Animal Foundation Chief Scientific Officer Janet Patterson-Kane, BVSc, PhD, FRCVS, said in a press release about the study.

While FHV-1 is a major cause of upper respiratory disease in the feline population, it’s also the most common cause of conjunctivitis. In extreme cases, the disease can cause corneal scarring and vision loss.

To help veterinarians more effectively treat this potentially blinding condition in shelter cars, researchers will conduct a clinical trial with more than 120 cats with evidence of FHV-1 eye infections from shelters in the Louisiana area. Each cat will receive one of three currently available antivirals (cidofovir, ganciclovir or famciclovir) or a placebo.

The researchers will score each cats’ eyes before and after one week of treatment to see whether any improvement has been made, as well as take eye swabs to measure the efficacy of each treatment. Researchers will then assess whether the virus develops any resistance to the antivirals by growing the swabbed samples in a lab in the presence of an antiviral. If the virus continues to grow, that could demonstrate resistance.

Researchers will also sequence the DNA of any bacteria isolated from affected cats to determine whether that bacteria are related to the therapeutic response. This will assess the impact of secondary eye infections, from which many cats with FHV-1 suffer.

“This virus can be debilitating, with outcomes pretty variable from cat to cat,” said Andrew Lewin, BVM&S, MRCVS, DACVO, assistant professor at LSU SVM and principal study investigator. “We want to be able to make a meaningful recommendation for veterinarians to improve the welfare of these animals.”

Related Content:

Feline MedicineInfectious DiseasesAnimal WelfareClinicalTechniciansAssociates
Free microchipping event to take place in Chicago
Free microchipping event to take place in Chicago
Study reveals most pet parents wouldn't leave home to escape disaster if they couldn't bring pets
Study reveals most pet parents wouldn't leave home to escape disaster if they couldn't bring pets
Workplace bottlenecks in the LGBTQIA+ community
Workplace bottlenecks in the LGBTQIA+ community

Advertisement

Latest News

I graduated veterinary school in 2023: Here are my takeaways

Life after coming out in veterinary medicine

Free microchipping event to take place in Chicago

Zoo announces birth of critically endangered red wolf pups

View More Latest News
Advertisement